Cargando…
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis
BACKGROUND: Although immune checkpoint inhibitors (ICIs) have improved survival for advanced wild-type non-small cell lung cancer (NSCLC), a lack of direct comparisons of various first-line treatments is clouding clinical decision-making. A network meta-analysis was conducted to compare current firs...
Autores principales: | Sheng, Lei, Gao, Jing, Xu, Qian, Zhang, Xue, Huang, Miao, Dai, Xin, Li, Song, Liu, Lian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165528/ https://www.ncbi.nlm.nih.gov/pubmed/34104227 http://dx.doi.org/10.1177/17588359211018537 |
Ejemplares similares
-
Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review
por: Kongnakorn, Thitima, et al.
Publicado: (2021) -
Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
por: Xu, Qian, et al.
Publicado: (2021) -
What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis
por: Zhang, Xue, et al.
Publicado: (2022) -
Undiscovered pathology of transient scaffolding t1remains a driver of failures in clinical trials
por: Kharlamov, Alexander N
Publicado: (2018) -
Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review
por: Triumbari, Elizabeth Katherine Anna, et al.
Publicado: (2022)